Immunome Inc. Revenue 2023–2025
Immunome Inc. annual/quarterly revenue history and growth rate from 2023 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Immunome Inc. revenue for the quarter ending March 31, 2026 was 0, a 100.00% decrease year-over-year.
- Immunome Inc. revenue for the twelve months ending March 31, 2026 was 6.9 M, a 29.66% decrease year-over-year.
- Immunome Inc. annual revenue for 2025 was 6.9 M, a 23.23% decrease from 2024.
- Immunome Inc. annual revenue for 2024 was 9.0 M, a 35.50% decrease from 2023.
- Immunome Inc. annual revenue for 2023 was 14.0 M.
Immunome Inc. (IMNM) — Frequently Asked Questions
Immunome Inc. (IMNM) is a publicly traded US company. It has a market capitalization of $1.59B. In fiscal 2025 it reported revenue of $7M and net income of -$212M. Explore IMNM's stock price, financial statements, earnings history, margins and key ratios below.
What is Immunome Inc.'s market cap?
Immunome Inc. (IMNM) has a market capitalization of $1.59B.
What is the IMNM stock price?
IMNM trades at $18.16 (-1.25% on the day).
How much revenue does Immunome Inc. make?
Immunome Inc. reported revenue of $7M in fiscal 2025.
Is IMNM profitable?
In fiscal 2025, Immunome Inc. reported net income of -$212M.